Should you invest in CRISPR Therapeutics (CRSP +0.18%) before the end of the year? The company's shares have slightly underperformed the broader market to date, but the biotech ma ...

Within the utilities sector, short interest at the end of August was spread broadly across the sector, with no single industry emerging as a clear standout or dominating in terms of positioning.

TV y streaming online de la semifinal de la Leagues Cup 2026 Toda la información sobre el Toluca contra León de la Leagues Cup 2026. The Sporting News Leagues Cup 2026: Resultados, posiciones, ...

Typewriter Therapeutics has emerged from stealth with $56 million in Series A funding co-led by AN Venture Partners and RA Capital Management, with participation from ANRI, Gemseki and SBI US Gateway ...

Editas Medicine (EDIT) stays a Hold as EDIT-401 nears trials; preclinical 90%+ LDL-C reduction for HeFH, but dilution and competition loom—read more macroanalysis here.

More foldables are set to use the display technology of the foldable iPhone.

Typewriter Therapeutics secures $56M Series A to develop in vivo CAR T gene therapy using non-viral RNA platform. Discover the breakthrough.

Budget phone shoppers in India just got another price hike to deal with. Vivo and its sub-brand iQOO have raised the prices ...

Vivo T5 debuts in India with a 6.83-inch 144Hz AMOLED screen, 7,050mAh battery, and Dimensity 7500 Turbo chip. It starts at ₹34,999 and launches on Sept 9.

The firm said it will stop enrolling a late-stage trial in blood cancers to prioritize a preclinical in vivo T-cell receptor program in solid tumors.

TScan Therapeutics (NASDAQ:TCRX) announced a strategic reorganization that includes a workforce reduction of approximately 75% as the company redirects resources toward an in vivo-engineered T cell ...

Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting ...